Codelivery of PEG-IFN-α inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys

Vaccine

Volumn 26, Issue 32, 2008, Pages 3978-3983

  Park, Su Hyung ^a   Lee, Sang Rae ^b   Hyun, Byung Hwa ^b   Kim, Byong Moon ^c   Sung, Young Chul ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

Author keywords

DNA vaccine; HCV; PEG IFN ; T cell response

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HEPATITIS C VACCINE; PEGINTERFERON ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CERCOPITHECIDAE; CHRONIC HEPATITIS; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; INTERFERON PRODUCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODY FORMATION; CERCOPITHECUS AETHIOPS; HEPACIVIRUS; HEPATITIS C; INTERFERON-ALPHA; T-LYMPHOCYTES; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

EID: 47149087508     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.017     Document Type: Article

References (34)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 8 (1999) 556-562
2. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S.C., Trepo C., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339 21 (1998) 1493-1499
3. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
4. Lechmann M., and Liang T.J. Vaccine development for hepatitis C. Semin Liver Dis 20 2 (2000) 211-226
5. Yang S.H., Lee C.G., Park S.H., Im S.J., Kim Y.M., Son J.M., et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13 14 (2006) 1110-1117
6. Ha S.J., Jeon B.Y., Kim S.C., Kim D.J., Song M.K., Sung Y.C., et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with mycobacterium tuberculosis. Gene Ther 10 (2003) 1543
7. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 14 6 (2001) 661-664
8. Belardelli F., and Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17 8 (1996) 369-372
9. Levy D.E., Marie I., and Prakash A. Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr Opin Immunol 15 1 (2003) 52-58
10. Taniguchi T., and Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14 1 (2002) 111-116
11. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 10 5 (1998) 383-390
12. Nguyen K.B., Salazar-Mather T.P., Dalod M.Y., Van Deusen J.B., Wei X.Q., Liew F.Y., et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 169 8 (2002) 4279-4287
13. Matikainen S., Paananen A., Miettinen M., Kurimoto M., Timonen T., Julkunen I., et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur J Immunol 31 7 (2001) 2236-2245
14. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191 10 (2000) 1777-1788
15. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 4 (1998) 1947-1953
16. Min W., Lillehoj H.S., Burnside J., Weining K.C., Staeheli P., and Zhu J.J. Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 20 1-2 (2001) 267-274
17. de Avila Botton S., Brum M.C., Bautista E., Koster M., Weiblen R., Golde W.T., et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 24 17 (2006) 3446-3456
18. Cheng G., Zhao X., Yan W., Wang W., Zuo X., Huang K., et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 25 28 (2007) 5199-5208
19. Takasu H. Interferon-alpha: an effective adjuvant for peptide-based cytotoxic T-cell vaccines. Kurume Med J 48 2 (2001) 171-174
20. Gehring S., Gregory S.H., Kuzushita N., and Wands J.R. Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol 75 2 (2005) 249-257
21. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 5 (2004) 346-355
22. Park S.H., Yang S.H., Lee C.G., Youn J.W., Chang J., and Sung Y.C. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 21 31 (2003) 4555-4564
23. Youn J.W., Park S.H., Lavillette D., Cosset F.L., Yang S.H., Lee C.G., et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42 6 (2005) 1429-1436
24. Rehermann B., Chang K.M., McHutchinson J., Kokka R., Houghton M., Rice C.M., et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70 10 (1996) 7092-7102
25. Kaser A., Molnar C., and Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 10 2 (1998) 75-81
26. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., and Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195 3 (2002) 327-333
27. Sriram U., Biswas C., Behrens E.M., Dinnall J.A., Shivers D.K., Monestier M., et al. IL-4 suppresses dendritic cell response to type I interferons. J Immunol 179 10 (2007) 6446-6455
28. Ruiz W., McClements W.L., Jansen K.U., and Esser M.T. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 3 1 (2005) 2
29. Guo J.T., Sohn J.A., Zhu Q., and Seeger C. Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology 325 1 (2004) 71-81
30. Sen G.C. Viruses and interferons. Annu Rev Microbiol 55 (2001) 255-281
31. Bekisz J., Schmeisser H., Hernandez J., Goldman N.D., and Zoon K.C. Human interferons alpha, beta and omega. Growth Factors 22 4 (2004) 243-251
32. Sheehan J.J., and Tsirka S.E. Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Glia 50 4 (2005) 340-350
33. Youn J.W., Park S.H., Cho J.H., and Sung Y.C. Optimal induction of T-cell responses against HCV E2 by antigen engineering in DNA immunization. J Virol 77 21 (2003) 11596-11602
34. Jo Y.W., Youn Y.S., Lee S.H., Kim B.M., Kang S.H., Yoo M., et al. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm 309 1-2 (2006) 87-93